# A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

> **NCT05883085** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Pheochromocytoma
- Paraganglioma

## Interventions

- **DRUG:** Anlotinib hydrochloride

## Key facts

- **NCT ID:** NCT05883085
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2024-05-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05883085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05883085, "A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05883085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*